ALGS Aligos Therapeutics

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. ET.

Jefferies Healthcare Conference Information:

Date:Thursday, June 8, 2023
Time:8:00 to 8:25 a.m. Eastern Time
Presenter:Lawrence Blatt, Ph.D., MBA, CEO of Aligos
Webcast:

A replay of the session will be available following the conference for 90-days through the Aligos investor section of the website .

The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Jefferies representative to schedule one-on-one meetings with Aligos during the conference.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).

Media Contact

Amy Jobe, Ph.D.

LifeSci Communications



Investor Contact

Corey Davis, Ph.D.

LifeSci Advisors





EN
24/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aligos Therapeutics

 PRESS RELEASE

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on ...

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company fo...

 PRESS RELEASE

Aligos Therapeutics Presents Positive Data at the Conference on Retrov...

Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the P...

 PRESS RELEASE

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on Jan...

 PRESS RELEASE

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates Interim analyses on track for the first and second half of 2026 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection. “2026 is an important year for Aligos as we continue to make...

 PRESS RELEASE

Aligos Therapeutics Strengthens Senior Leadership Team with the Appoin...

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer Seasoned leader with global commercialization and marketing expertise SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (“Aligos”, Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch